NASDAQ:GERN Geron Q2 2026 Earnings Report $1.44 -0.02 (-1.03%) As of 02:51 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Geron EPS ResultsActual EPSN/AConsensus EPS -$0.01Beat/MissN/AOne Year Ago EPSN/AGeron Revenue ResultsActual RevenueN/AExpected Revenue$55.30 millionBeat/MissN/AYoY Revenue GrowthN/AGeron Announcement DetailsQuarterQ2 2026Date8/5/2026TimeBefore Market OpensConference Call DateWednesday, August 5, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Geron Earnings HeadlinesGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 22, 2026 | globenewswire.comGeron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026July 22, 2026 | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.July 29 at 1:00 AM | Banyan Hill Publishing (Ad)Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive ChairmanJuly 15, 2026 | globenewswire.comGeron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 14, 2026 | globenewswire.comGeron (GERN) Grants Inducement Stock Options to New EmployeesJuly 14, 2026 | insidermonkey.comSee More Geron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Geron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Geron and other key companies, straight to your email. Email Address About GeronGeron (NASDAQ:GERN) (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options. The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes. Imetelstat works by directly binding to the RNA template of telomerase, thereby blocking the enzyme’s activity and shortening telomeres in malignant cells. Preclinical studies have also explored potential applications of telomerase inhibition in various solid tumors. Founded in 1990 by researchers Elizabeth Blackburn, Carol Greider and Jack Szostak—who later received the Nobel Prize in Physiology or Medicine for their work on telomeres—Geron is headquartered in Foster City, California. The company has established collaborations and licensing agreements with academic institutions, contract research organizations and pharmaceutical partners to advance its clinical programs and expand its research capabilities. Under the leadership of CEO John A. Scarlett, Geron continues to build its infrastructure for late-stage clinical development. The company serves a global community of physicians, researchers and patients by conducting multi-center clinical trials across North America and Europe, with the goal of bringing telomerase-targeted therapies to market.View Geron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Bloom Energy May Be the Most Important AI Infrastructure StockCarrier Earnings Could Send the Stock to a New All-Time High3 Refiners Benefiting From Oil Volatility and Tight Fuel SupplyWelltower at 52-Week Highs—But Analysts Believe There's More to ComeThese 3 Stocks Have Soared in 2026—Can They Keep Climbing?UPS Just Gave Investors a Second Chance to BuyHasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Upcoming Earnings Ferrari (7/30/2026)Air Products and Chemicals (7/30/2026)ArcelorMittal (7/30/2026)Vale (7/30/2026)Mastercard (7/30/2026)Apple (7/30/2026)ASE Technology (7/30/2026)Monolithic Power Systems (7/30/2026)CRH (7/30/2026)Quanta Services (7/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
